Cart
sales@molnova.com
Lixisenatide
CAS No. 320367-13-3
Lixisenatide( —— )
Catalog No. M30039 CAS No. 320367-13-3
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).It is an injectable diabetes medicine that helps control blood sugar levels.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 162 | Get Quote |
|
| 5MG | 214 | Get Quote |
|
| 10MG | 365 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
Biological Information
-
Product NameLixisenatide
-
NoteResearch use only, not for human use.
-
Brief DescriptionLixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).It is an injectable diabetes medicine that helps control blood sugar levels.
-
DescriptionLixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).It is an injectable diabetes medicine that helps control blood sugar levels.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorGLP-1 receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number320367-13-3
-
Formula Weight4858.49
-
Molecular FormulaC215H347N61O65S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?H2O : 100 mg/mL (20.58 mM)
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
QS-21
QS-21, an immunostimulatory saponin, is a powerful vaccine adjuvant that stimulates both Th2 humoral and Th1 cell-mediated immune responses by interacting with antigen presenting cells (APCs) and T cells.
-
Leucokinin I
Leucokinin I
-
Adenine sulfate
Adenine sulfate is a sulfate salt form of adenine which is a purine derivative and a nucleobase with a variety of roles in biochemistry.
